Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913

Yoshiro Nakahara1,2,3 · Tsuneo Shimokawa4 · Yuki Misumi4 · Naoyuki Nogami5 · Tetsu Shinkai5,6 · Nobuhiko Seki7 · Yukio Hosomi1 · Naoya Hida4,8 · Hiroaki Okamoto4

Received: 19 June 2020 / Accepted: 6 August 2020 / Published online: 15 August 2020 © The Author(s) 2020

Summary

Introduction In preclinical data, the combination therapy with S-1 and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) had a synergistic antitumor effect on non-small cell lung cancer (NSCLC), regardless of the EGFR mutation status. Patients and Methods Patients with previously treated NSCLC and adequate organ function regardless of EGFR mutation status were eligible for the phase I study, with wild-type EGFR were eligible for the phase II study. Treatment consisted of erlotinib 150 mg/body orally once every day and S-1 60 mg/m2, 70 mg/m2, or 80 mg/m2 (level 0, level 1, or level 2) orally on days 1–14 every three weeks. The primary endpoint for the phase I study was the determination of the recommended dose (RD), the phase II study was the overall response rate (ORR). Results A total of 7 patients with performance-status (PS) 0 or 1 were enrolled as subjects in phase I. Five of these subjects were EGFR-mutation positive. Four subjects were enrolled at S-1 dose level 1 and 3 were enrolled at S-1 dose level 2. No dose-limiting toxicities were observed in these subjects. The RD was decided as erlotinib 150 mg/body and S-1 80 mg/m2. In phase I, 5 subjects achieved partial response, and the ORR was 71.4%. A total of 10 patients with PS 0, 1, or 2 EGFR-wild type NSCLC were enrolled in phase II. In phase II, the ORR was 10.0%, and the disease control rate (DCR) was 40.0%. After the enrollment of 10 subjects, enrollment was stopped based on two treatment-related deaths. Conclusion The combination therapy of erlotinib plus S-1 was not feasible in the EGFR wild-type NSCLC at least and early stopped. Trial registration: UMIN-CTR Identifier: 000003421 (2010/03/31, phase I), 000003422 (2010/03/31, Phase II).

Keywords Epidermal growth factor receptor tyrosine kinase inhibitor · Erlotinib · S-1 · Non-small cell lung cancer

1 Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan
2 Department of Respiratory Medicine, Kitasato University School of Medicine, 1-15-1, Kitasato, Minami-ku, Sagamihara, Kanagawa 252-0374, Japan
3 Department of Thoracic Oncology, Kanagawa Cancer Center, 2-3-2, Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515, Japan
4 Department of Respiratory Medicine, Yokohama Municipal Citizen’s Hospital, 56 Okazawa-cho, Hodogaya-ku, Yokohama, Kanagawa 240-8555, Japan
5 Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, 160 Kou Minami-Umemoto, Matsuyama, Ehime 791-0280, Japan
6 Department of Medical Oncology, Shonan Eastern General Hospital, 500, Nishikubo, Chigasaki, Kanagawa 253-0083, Japan
7 Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo 173-0014, Japan
8 Department of Respiratory Medicine, Yokohama-City Seibu Hospital of St. Marianna University School of Medicine, 1197-1, Yasashi-cho, Asahi-ku, Yokohama, Kanagawa 241-0811, Japan

Yoshiro Nakahara
md100062@kcch.jp
**Introduction**

Lung cancer is the leading cause of cancer deaths worldwide. Effective treatment options for patients with non-small cell lung cancer (NSCLC) whose disease progresses after first-line platinum-based chemotherapy are limited. In the patients without driver oncogene, immune checkpoint inhibitors of anti-programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) are now standard second-line treatments [1–4]. For patients who have failed or are not eligible for immunotherapy, docetaxel [5, 6]—with or without ramucirumab [7]—or pemetrexed [8] are other standard therapies in case of relapsed NSCLC.

Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed a significant overall survival benefit in a randomized phase III trial in previously treated advanced NSCLC, regardless of EGFR mutation status [9].

S-1 is an oral fluoropyrimidine-based combination of tegafur, gimeracil, and oteracil potassium in a molar ratio of 1:0:4:1. A randomized phase III study showed non-inferiority of S-1 monotherapy to docetaxel for overall survival in previously treated patients who had undergone at least 1 platinum-based chemotherapy [10]. In that study, significant improvement was shown in the EORTC QLQ-C30 global health status in the S-1 arm.

The combination therapy with S-1 and gefitinib had a synergistic antitumor effect on NSCLC xenografts in vivo, regardless of EGFR mutation status [11]. The synergistic antitumor effect is considered due to Gefitinib-induced down-regulation of thymidylate synthase (TS). Furthermore, Giovannetti E, et al. reported that erlotinib also significantly reduced TS expression and activity, possibly via E2F-1 reduction [12]. Thus, the combination therapy of S-1 and erlotinib might be a promising strategy.

We therefore planned this phase I/II clinical study to evaluate the efficacy and safety of combination therapy of S-1 and erlotinib for previously treated NSCLC.

**Methods**

**Patients**

**(Phase I study)**

Patients with stage IIIB or IV cytologically or histologically confirmed NSCLC who had disease progression after one or two prior platinum-containing regimens, regardless of EGFR mutation status, were eligible for participation in the study. Eligible patients were 20 years of age or older; had an Eastern Cooperative Group (ECOG) performance-status (PS) score of 0 or 1; at least 1 measurable target lesion; and no prior chemotherapy with EGFR-TKI or fluoropyrimidine.

The criteria for adequate organ function included white blood cell (WBC) count ≥3500 - ≤12,000/μL, neutrophil count ≥2000/μL, platelet count ≥100,000/μL, hemoglobin ≥9.5 g/dL, serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) concentrations ≤2.5 × upper limit of normal (ULN), creatinine level 1.5 × ULN, creatinine clearance ≥60 mL/min, oxygen saturation by pulse oximetry ≥90%.

Patients were excluded from the study if they had interstitial pneumonia or pulmonary fibrosis on chest X-ray, symptomatic brain metastases, massive pleural/pericardial effusion or ascites, or severe concomitant disease.

**(Phase II study)**

Patients with stage IIIB or IV cytologically or histologically confirmed NSCLC with wild-type EGFR who had disease progression after one or two prior platinum-containing regimens were eligible for participation in the phase II study.

An in vitro experiment showed that EGFR wild-type cells are more sensitive to fluorouracil than mutant cells [13]. Based on this data, we decided that the main purpose of the phase II study was to analyze the efficacy of this combination therapy for the patients with wild-type EGFR. Thus, only the patients with wild-type EGFR were enrolled. Eligible patients were 20 years of age or older; had an ECOG PS of 0–2; at least 1 measurable target lesion; and no prior chemotherapy with EGFR-TKI or fluoropyrimidine. Because of the good tolerability observed in the phase I study, PS 2 patients were also enrolled in the phase II study.

The criteria for adequate organ function were almost the same as those of phase I study. However, oxygen saturation by pulse oximetry needed to be ≥94% in the phase 2 section. The exclusion criteria were the same as those of phase I study.

Written informed consent was obtained from every subject. The study protocol was approved by the Thoracic Oncology Research Group (TORG) Protocol Review Committee and the review board of each participating institution.

**Evaluation for enrollment**

All patients were required to undergo CT of the thorax and the upper abdomen, either CT or magnetic resonance imaging (MRI) of the brain, and either radioisotope bone scan or positron emission tomography (PET) for the assessment of disease stage. A complete blood cell count and a blood chemistry test were performed at the enrollment.

In the phase II study, EGFR mutation status was analyzed with peptide nucleic acid, locked nucleic acid polymerase chain reaction (PNA-LNA PCR) clamp method, PCR-I invader method (structure-specific 5’ nucleic-based method), direct sequence method, or Scorpion ARMS method.
After the protocol treatment was started, chest X-ray and blood testing were performed at least once a week in the phase 1 section, and once per cycle in the phase 2 study. CT was repeated every month to evaluate the target lesions. Tumor response was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.

Phase I study

The primary endpoint for the phase I study was the determination of the recommended dose (RD). Erlotinib 150 mg/body was administered orally once a day (Fig. 1). S-1 was also given orally, twice daily after meals for 2 weeks in a 3-week cycle. Based on previous studies, the following dose levels of S-1 were evaluated: level 0, 60 mg/m²; level 1, 70 mg/m²; and level 2, 80 mg/m² (Table 1). S-1 dose was based on body surface area (Table 1). The study treatment was started at level 1.

The dose level was escalated based on the development of toxicity during the treatment, and was not escalated for every subject. Dose-limiting toxicity (DLT) was considered to be any of the following adverse events: grade 4 leukopenia or thrombocytopenia; grade 3 febrile neutropenia; grade 3 non-hematologic toxicity except for nausea, vomiting, anorexia, and alopecia; grade 4 AST/ALT elevation, or grade 3 AST/ALT elevation lasting 7 days or more; serum bilirubin elevation greater than 3.5 mg/dl, or 2.5–3.5 mg/dl lasting 7 days or more; any delay of scheduled oral intake of erlotinib and/or S-1 for 2 weeks or more; or grade 1 ILD with suspected association with the therapeutic drugs. The dose escalation was made, in principle, according to the DLT frequency in the first cycle at a particular dose level. Three subjects were initially enrolled at level 1; if no DLT was observed, then the 3 subjects were to receive level 2 treatment. If 1 of the initial 3 subjects receiving level 1 treatment developed DLT, we were to define the dose of level 1 as MTD. If all 3 of the initial 3 subjects receiving level 1 treatment developed DLT, we were to define the dose of level 1 as MTD. One level under MTD was to be defined as RD. If the level 1 treatment was MTD, we were to continue this study with level 0 therapy. If no DLT was observed in level 2 treatment, we were to define level 2 dose as RD.

Phase II study and statistical analysis

Phase II study was performed based on RD decided in phase I. The primary endpoint of the phase II study was the overall response rate (ORR). Based on the Simon two-stage design, the planned sample size of 50 subjects was determined appropriate to reject a null ORR of 5% at one-sided significance level of 0.05 under an expected ORR of 16% with a power of 0.80. The secondary endpoints were disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and toxicity. The Kaplan–Meier method was used to estimate the median values of time-to-events, such as OS and PFS; and the confidence intervals (CIs) were calculated using the Brookmeyer and Crowley method. All statistical analyses were performed using BellCurve for Excel (Social Survey Research Information, Tokyo, Japan).

Results

Baseline characteristics

A total of 7 and 10 subjects were enrolled in phase I and phase II, respectively, from 5 institutions across Japan from October 2010 to April 2012. Enrollment was stopped when 10 subjects were enrolled in phase II study, following the Safety Review Committee’s recommendation based on two treatment-related deaths (TRD). In phase I study, five subjects were EGFR-mutation positive. Subject demographics and disease characteristics are summarized in Table 2.

Phase I MTD and DLT

The phase I study included 7 subjects (Table 3). At level 1, 4 subjects were evaluated, and no subjects developed DLT. The dose was then escalated to level 2, in which 3 subjects were

---

**Fig. 1** Treatment schedule

| Erlotinib: 150 mg/body/day |
|---------------------------|
| S-1                       |

Day 1 | Day 14 | Day 21
enrolled and treated. At level 2, no subjects developed DLT. Thus, level 2 was considered to be the RD. Toxicities in phase I study are summarized in Table 4.

Efficacy

In phase I study, among 7 subjects, 5 subjects achieved partial response (PR), 1 subject had stable disease (SD), and 1 subject had progressive disease (PD). Thus, the ORR was 71.4%, and the disease control rate (DCR) was 85.7%. In phase II study, among 10 subjects, 1 subject achieved partial response (PR), 3 subjects had stable disease (SD), 3 subjects had progressive disease (PD), and 3 subjects were not evaluable (NE). Thus, the ORR was 10.0%, and the disease control rate (DCR) was 40.0%. The data regarding efficacy are summarized in Table 5.

Toxicities in phase II study

Toxicities in phase II study are summarized in Table 4. The protocol treatment was stopped in 4 subjects due to adverse effects: grade 3 diarrhea in 2 subjects, hyperbilirubinemia (total bilirubin: 3.5) in 1 subject, and grade 3 dehydration in 1 subject. There were two TRDs: 1 subject died because of acute respiratory failure on day 65, caused by pulmonary embolism based on pathological anatomy; 1 subject died because of sepsis due to diarrhea and bacterial enteritis on day 25. Enrollment was stopped, following the recommendation of the Safety Review Committee based on these two TRDs.

Treatment cycle

Treatment cycles in phase I and phase II studies are shown in Table 6. In phase I study, 3 subjects (43%) continued more than 6 cycles (6, 12, and 17 cycles). On the other hand, in phase II section, 5 subjects (50%) discontinued protocol treatment after the 1st cycle. Only 1 subject (10%) continued more than 6 cycles (8 cycles).

Discussion

This phase II study in patients with previously treated NSCLC with wild type EGFR revealed that the combination therapy of erlotinib and S-1 was not feasible, and the enrollment was stopped, following the recommendation of the Safety Review Committee based on two TRDs.

The cause of difference between toxicities in the phase I study and the phase II study might have been due to the difference in study populations in phase I and phase II. In phase I, the inclusion criteria allowed enrollment of EGFR-mutated patients, and 5 EGFR-mutated subjects and no subjects with squamous cell carcinoma were enrolled. Furthermore, the inclusion criteria allowed only PS 0 and 1 patients, and 6 subjects were enrolled as second-line setting. These subject characteristics led to the high efficacy and tolerability observed in the phase I study. Kiyota, et al. reported good tolerability of gefitinib and S-1 combination therapy [14]. In that study, subjects with only adenocarcinoma were enrolled, and all subjects enrolled in that study were PS 0, or 1. On the other hand, in the
### Table 4 Toxicities

|                | Phase I (n = 7) |         |         |         | Phase II (n = 10) |         |         |         |
|----------------|----------------|---------|---------|---------|------------------|---------|---------|---------|
|                | Grade 1/2      | Grade 3 | Grade 4 | All Grade | Grade 1/2        | Grade 3 | Grade 4 | All Grade |
| Decreased appetite | 2              | 0       | 0       | 28.6%    | 0%               | 7       | 1       | 0       | 80.0%    | 10.0% |
| Nausea         | 3              | 0       | 0       | 42.9%    | 0%               | 5       | 0       | 0       | 50.0%    | 0%   |
| Vomiting       | 0              | 0       | 0       | 0%       | 0%               | 4       | 0       | 0       | 40.0%    | 0%   |
| Diarrhea       | 1              | 0       | 0       | 14.3%    | 0%               | 7       | 2       | 0       | 90.0%    | 20.0% |
| Oral mucositis | 4              | 0       | 0       | 57.1%    | 0%               | 5       | 1       | 0       | 60.0%    | 10.0% |
| Rash/desquamation | 6             | 0       | 0       | 85.7%    | 0%               | 5       | 1       | 0       | 60.0%    | 10.0% |
| Rash/acneiform | 3              | 0       | 0       | 42.9%    | 0%               | 2       | 1       | 0       | 30.0%    | 10.0% |
| Rash/hand-foot skin reaction | 1     | 0       | 0       | 14.3%    | 0%               | 1       | 1       | 0       | 20.0%    | 10.0% |
| Hyperpigmentation | 1             | 0       | 0       | 14.3%    | 0%               | 2       | 0       | 0       | 20.0%    | 0%   |
| Dry skin       | 1              | 0       | 0       | 14.3%    | 0%               | 4       | 0       | 0       | 40.0%    | 0%   |
| Pruritus       | 2              | 0       | 0       | 28.6%    | 0%               | 2       | 0       | 0       | 20.0%    | 0%   |
| Paronychia     | 0              | 0       | 0       | 0%       | 0%               | 0       | 1       | 0       | 10.0%    | 10.0% |
| Fatigue        | 4              | 0       | 0       | 57.1%    | 0%               | 2       | 0       | 0       | 20.0%    | 0%   |
| Fever          | 0              | 0       | 0       | 0%       | 0%               | 2       | 0       | 0       | 20.0%    | 0%   |
| Dehydration    | 0              | 0       | 0       | 0%       | 0%               | 0       | 1       | 1       | 20.0%    | 20.0% |
| Hypotension    | 0              | 0       | 0       | 0%       | 0%               | 0       | 1       | 1       | 20.0%    | 20.0% |
| Hemorrhagic gastric ulcer | 0    | 0       | 0       | 0%       | 0%               | 0       | 1       | 0       | 10.0%    | 10.0% |
| Colitis        | 0              | 0       | 0       | 0%       | 0%               | 0       | 0       | 1       | 10.0%    | 10.0% |
| Sepsis         | 0              | 0       | 0       | 0%       | 0%               | 0       | 1       | 1       | 10.0%    | 10.0% |
| Leukocytopenia | 2              | 0       | 0       | 28.6%    | 0%               | 0       | 0       | 0       | 0%       | 0%   |
| Neutropenia    | 2              | 0       | 0       | 28.6%    | 0%               | 0       | 0       | 0       | 0%       | 0%   |
| Anemia         | 3              | 0       | 0       | 42.9%    | 0%               | 5       | 0       | 0       | 50.0%    | 0%   |
| Thrombocytopenia | 1            | 0       | 0       | 14.3%    | 0%               | 1       | 1       | 0       | 20.0%    | 10.0% |
| Hyperbilirubinemia | 4          | 1       | 0       | 71.4%    | 14.3%            | 5       | 0       | 0       | 50.0%    | 0%   |
| Aspartate aminotransferase elevation | 2       | 0       | 0       | 28.6%    | 0%               | 1       | 0       | 0       | 10.0%    | 0%   |
| Alanine aminotransferase elevation | 1       | 1       | 0       | 28.6%    | 14.3%            | 1       | 0       | 0       | 10.0%    | 0%   |
| Alkaline phosphatase elevation | 1       | 0       | 0       | 14.3%    | 0%               | 2       | 0       | 0       | 20.0%    | 0%   |
| Creatinine elevation | 2       | 0       | 0       | 28.6%    | 0%               | 2       | 0       | 0       | 20.0%    | 0%   |

### Table 5 Treatment efficacy

|                | Phase I (n = 7) | Phase II (n = 10) | Total (n = 17) |
|----------------|-----------------|-------------------|---------------|
|                | CR              | PR                | SD            |
|                | 0               | 0                 | 5             |
|                | PR              | 0                 | 1             |
|                | 6               |                   |               |
|                | SD              | 3                 | 4             |
|                | 1               | 3                 | 4             |
|                | NE              | 0                 | 3             |
|                | 3               | 3                 |               |
|                | RR              | 71.4%             | 10.0%         |
|                | 35.3%           | 58.8%             |               |
|                | DCR             | 85.7%             | 40.0%         |
|                |               | 58.8%             |               |

**CR** complete response, **DCR** disease control rate, **NE** not evaluable, **PD** progressive disease, **PR** partial response, **RR** response rate, **SD** stable disease

### Table 6 Treatment cycles

|                | Phase I (n = 7) | Phase II (n = 10) | Total (n = 17) |
|----------------|-----------------|-------------------|---------------|
|                | 1 cycle         | 2                 | 5             |
|                | 2 cycles        | 1                 | 0             |
|                | 3 cycles        | 1                 | 3             |
|                | 4 cycles        | 0                 | 1             |
|                | 5 cycles        | 0                 | 0             |
|                | 6 cycles        | 1                 | 0             |
|                | 7 cycles        | 0                 | 0             |
|                | More than 8 cycles | 2         | 1             |
|                |                 | 3                 |               |
phase II of our study, the inclusion criteria did not allow enrollment of EGFR-mutated patients; all subjects were EGFR wild type, and 4 subjects with squamous cell carcinoma were enrolled. Several trials showed that the efficacy of erlotinib for non-adenocarcinoma [9, 15], or smokers [9, 16] was poor. Furthermore, in the phase II of our study, the inclusion criteria allowed PS 0–2 patients; 2 PS 2 subjects were enrolled, and 7 subjects were enrolled as third-line setting. These subject characteristics led to the low efficacy and strong toxicity observed in the phase II of our study. In our study, although RD was decided appropriately in phase I study, due to the differences in inclusion criteria, serious adverse events frequently occurred in phase II study.

Treatment for cancer now can be individualized based on the molecular testing profile of the cancer. Many trials showed that EGFR-TKIs have remarkable efficacy in patients with EGFR activating mutations. These genotyping-guided treatments have been effective in clinical practice. Along with these trials, the role of EGFR-TKIs in patients with wild-type EGFR had been discussed. The Tarceva Italian Lung Optimization Trial (TAILOR) was a randomize phase III trial that compared erlotinib and docetaxel as second-line treatment of patients with advanced NSCLC with wild-type EGFR [17]. That trial showed that docetaxel superior to erlotinib in terms of overall survival (OS), progression-survival of survival (PFS), and response rate (RR). Furthermore, a subgroup analysis of a Japanese randomized phase III trial showed that PFS and RR with docetaxel were significantly better than those of erlotinib in patients with wild-type EGFR [15]. In that analysis, though not statistically significant, OS of docetaxel tended to be better than that of erlotinib. From these data, in patients with wild-type EGFR, the efficacy of erlotinib is seen to be limited.

Several trials of erlotinib and cytotoxic chemotherapy combination have been performed. However, in those trials, the combination therapy did not confer a survival advantage over cytotoxic chemotherapy alone in unselected patients [18, 19]. On the other hand, in EGFR-mutant NSCLC, the combination therapy of EGFR-TKI and cytotoxic chemotherapy showed promising efficacy. Some clinical trials that analyzed the combination of EGFR-TKI and pemetrexed were reported. The JMII study, an open-label randomized phase II study, compared the combination therapy of gefitinib and pemetrexed versus gefitinib monotherapy [20], and showed the median PFS with gefitinib and pemetrexed was significantly longer than that with gefitinib alone [15.8 vs 10.9 months; adjusted Hazard Ratio (HR) 0.68; 95% CI, 0.48–0.96; \( P = .029 \)]. Study NEJ009, a randomized phase III study, compared gefitinib monotherapy with gefitinib plus pemetrexed and carboplatin, and showed that gefitinib plus pemetrexed and carboplatin demonstrated better ORR and PFS than the gefitinib monotherapy (ORR, 84% v 67% [\( P < .001 \)]; PFS, 20.9 v 11.9 months; HR for death or disease progression, 0.490 [\( P < .001 \)] [21]. In that study, median OS in the gefitinib plus pemetrexed and carboplatin group was also significantly longer than in the gefitinib monotherapy group (50.9 v 38.8 months; HR for death, 0.722; \( P = .021 \)). Furthermore, another randomized phase III study of the same design also showed that gefitinib plus pemetrexed and carboplatin demonstrated better ORR, PFS, and OS than the gefitinib monotherapy (ORR, 75% v 63% [\( P = .01 \)]; PFS, 16 v 8 months; HR for death or disease progression, 0.51 [\( P < .001 \)]; OS, not reached v 17 months; HR for death, 0.45 [\( P < .001 \)] [22]. Based on these data, in patients with EGFR-mutant NSCLC, the combination therapy of pemetrexed and EGFR-TKI would seem promising. The rationale for combining pemetrexed and EGFR-TKI is the suppression of TS by EGFR-TKI. Therefore, it was concluded that combination therapy of erlotinib and S-1 might be effective for EGFR-mutant NSCLC.

The main limitation of the present study was that it was a clinical trial with small sample size. Also, since many trials showed that the efficacy of erlotinib was limited in patients with wild-type EGFR, the significance of combination therapy in unselected patients had faded. Furthermore, other, more effective drugs such as immune checkpoint inhibitors have been established as the standard treatments based on large phase III studies, and thus the expectations for the combination therapy of erlotinib plus S-1 had declined.

In conclusion, the combination therapy of erlotinib and S-1 was not feasible in the EGFR wild-type NSCLC at least and early stopped.

Acknowledgements We thank the subjects and their families for their support and participation in this study. We thank the data management staff of the Thoracic Oncology Research Group (TORG), especially Yumiko Tanabe and Hiroyuki Kashiro. The authors also thank Dr. Keiichi Nagao, Dr. Kiyoshi Mori, Dr. Ryuji Ikeda, and Dr. Masahiko Kusumoto for management and recommending the present clinical trial as the Data and Safety Monitoring Committee.

Author’s contributions NN and TShinok conceived and designed the study. YN, TShimok, YM, NN, TShink, NS, YH, NH, and HO acquired the data. YN analyzed the data and wrote the manuscript. All authors gave approval of the final version of the manuscript.

Funding This research was supported by the Thoracic Oncology Research Group (TORG).

Availability of data and material The data and materials used in this study are available from the corresponding author on reasonable request.

Compliance with ethical standards Conflict of interest YN received honoraria from MSD K.K., Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Bristol-Myers Squibb, and Nippon Boehringer Ingelheim Co., Ltd.; and research funding from Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb, and Eli Lilly Japan K.K.

TShimok received research funding from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., and Bristol-Myers Squibb.
YM has nothing to disclose.

NN received honoraria from MSD K.K., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Taiho Pharmaceutical Co., Ltd., and Chugai Pharmaceutical Co., Ltd.; and research funding from AstraZeneca K.K., Taiho Boehringer Ingelheim Co., Ltd., Eli Lilly Japan K.K., and Kyowa Kirin Co., Ltd.

TShink has nothing to disclose.

NS received honoraria from AstraZeneca K.K., Taiho Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Company, Limited, Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Taiho Pharmaceutical Co., Ltd., and Chugai Pharmaceutical Co., Ltd.; and research funding from AstraZeneca K.K., Taiho Boehringer Ingelheim Co., Ltd., and Nihon Medi-Physics Co., Ltd.

YH received honoraria from Eli Lilly Japan K.K., AstraZeneca K.K., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Kyowa Kirin Co., Ltd., and CSL Behring K.K.

NH has nothing to disclose.

HO received a grant from Japan Agency for Medical Research and development (AMED); and research funding from Takeda Pharmaceutical Company Limited, MSD K.K., Ono Pharmaceutical Co., Ltd., AstraZeneca K.K., Merck KGaA, Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Eli Lilly Japan K.K., and Daiichi Sankyo Company, Limited.

Ethics approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the institutional review boards of all participating sites.

Consent to participate All study participants provided written informed consent prior to enrollment.

Consent for publication Not applicable.

Code availability Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Pollock J, Barrios C, Kabbavafar F, Frontera OA, de Marinis F, Tuma H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR. OAK Study Group (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer. N Engl J Med 373:1627–1639

2. Rittmeyer A, Basli F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Pollock J, Barrios C, Kabbavafar F, Frontera OA, de Marinis F, Tuma H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR. OAK Study Group (2017) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:255–265

3. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro GJ, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550

4. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RA, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L, the TAX320 Non–Small-Cell Lung Cancer Study Group (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18(12):2354–2362

5. Shepherd FA, Dansey J, Ramlau R, Matsson K, Gralla R, O’Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18(10):2095–2103

6. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalszyn SD, Ptkiel J, Czyzewicz G, Orlov SV, Lewanski CR, Thomas M, Bidoli P, Dakhil S, Gans S, Kim JH, Grigorescu A, Karaseva N, Reck M, Cappuzzo F, Alexandris E, Sashgey A, Yurasov A, Peral M (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665–673

7. Hanna N, Shepherd FA, Fossella FV, Pereira J, de Marinis F, von Pawel J, Gatzemeier U, Tsao TCY, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar Manegold C, Paul S, Paolotti P, Einhorn L, Bunn PA Jr (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22(9):1589–1597

8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dedi M, Findlay B, Tu D, Johnston D, Bezzak A, Clark G, Santabárbara P, Seymour L, National Cancer Institute of Canada Clinical Trials Group (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132

9. Nokihara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, Zhang L, Soo RA, Yang JC, Sugawara S, Nishio M, Takahashi T, Goto K, Chang J, Maemondo M, Ichinose Y, Cheng Y, Lim WT, Morita S, Tamura T (2017) Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer

Disclaimer

© Springer
11. Okabe T, Okamoto I, Tsuikioka S, Uchida J, Ibasa T, Yoshida T, Hatashita E, Yamada Y, Satoh T, Tamura K, Kukuoka M, Nakagawa K (2008) Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Mol Cancer Ther 7(3):599–606

12. Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Ricciardi S, Danesi R, Giaccone G, Peters GJ (2008) Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 73:1290–1300

13. Suehisa H, Toyooaka S, Hotta K, Uchida A, Soh J, Fujiwara Y, Matsuo K, Ouchida M, Takata M, Kiura K, Date H (2007) Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. J Clin Oncol 25(25):3952–3957

14. Kiyota H, Okamoto I, Takeda M, Daga H, Naito T, Miyazaki M, Okada H, Hayashi H, Tanaka K, Terasima M, Azuma K, Murakami H, Takeda K, Yamamoto N, Nakagawa K (2013) Phase I and pharmacokinetic study of Gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. Cancer Chemother Pharmacol 71(4):859–865

15. Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, Ibata H, Kozuki T, Endo T, Tamura A, Kaminura M, Sakamoto K, Yoshimi M, Soejima Y, Tomizawa Y, Ito SI, Takada M, Saka H, Kubo A (2014) Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer trial (DELTAS). J Clin Oncol 32(18):1902–1908

16. Kubota K, Nishiwaki Y, Tamura T, Nakagawa K, Matsui K, Watanabe K, Hida T, Kawahara M, Katakami N, Takeda K, Yokoiyama A, Noda K, Kukuoka M, Saijo N (2008) Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small-cell lung cancer: a phase II study. J Thorac Oncol 3:1439–1445

17. Garassino MC, Martelli O, Broggi M, Farina G, Veronesi S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauritcella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S (2013) Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 14:981–988

18. Herbstr RS, Prager D, Herrmann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA, TRIBUTE Investigator Group (2005) TRIBUTE: a phase III trial of Erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung Cancer. J Clin Oncol 23(25):5892–5899

19. Gatzemeier U, Pluzanska A, Szeszewska A, Kaukel E, Roubec J, de Rosa F, Milanowski J, Karmicka-Mlodkowski H, Pesek M, Serwatowski P, Ramlau R, Janaskova T, Vansteenkiste J, Strausz J, Manikhas GM, von Pawel J (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25(12):1545–1552

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.